Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NTLA Intellia Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: NTLA
Price (delayed)
$12.16
Market cap
$1.26B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.22
Enterprise value
$1.25B
Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron.
Highlights
The EPS has grown by 2.6% YoY
The company's debt fell by 43% QoQ but it rose by 8% YoY
The company's quick ratio fell by 46% YoY and by 17% QoQ
Intellia Therapeutics's equity has decreased by 25% YoY and by 11% from the previous quarter
Key stats
What are the main financial stats of NTLA
Market
Valuations
Earnings
Shares outstanding
103.58M
Market cap
$1.26B
Enterprise value
$1.25B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.61
Price to sales (P/S)
27.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.47
Revenue
$45.57M
Gross profit
$45.57M
Operating income
-$541.07M
Net income
-$525.91M
EBIT
-$525.91M
EBITDA
-$515.64M
Free cash flow
-$381.16M
Per share
Balance sheet
Liquidity
EPS
-$5.22
EPS diluted
-$5.22
Free cash flow per share
-$3.68
Book value per share
$7.53
Revenue per share
$0.44
TBVPS
$9.53
Total assets
$986.16M
Total liabilities
$206.24M
Debt
$119.25M
Equity
$779.92M
Working capital
$438.8M
Debt to equity
0.15
Current ratio
4.9
Quick ratio
4.57
Net debt/EBITDA
0.01
Margins
Efficiency
Dividend
EBITDA margin
-1,131.6%
Gross margin
100%
Net margin
-1,154.1%
Operating margin
-1,187.4%
Return on assets
-46.3%
Return on equity
-58.7%
Return on invested capital
-51.6%
Return on capital employed
-60.2%
Return on sales
-1,154.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NTLA stock price
How has the Intellia Therapeutics stock price performed over time
Intraday
0.25%
1 week
13.22%
1 month
43.57%
1 year
-47.47%
YTD
4.29%
QTD
29.64%
Financial performance
How have Intellia Therapeutics's revenue and profit performed over time
Revenue
$45.57M
Gross profit
$45.57M
Operating income
-$541.07M
Net income
-$525.91M
Gross margin
100%
Net margin
-1,154.1%
Intellia Therapeutics's operating margin has decreased by 29% QoQ and by 21% YoY
The company's net margin fell by 29% QoQ and by 25% YoY
Intellia Therapeutics's revenue has decreased by 21% QoQ and by 13% YoY
The gross profit has contracted by 21% from the previous quarter and by 13% YoY
Price vs fundamentals
How does NTLA's price correlate with its fundamentals
Growth
What is Intellia Therapeutics's growth rate over time
Valuation
What is Intellia Therapeutics stock price valuation
P/E
N/A
P/B
1.61
P/S
27.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.47
The EPS has grown by 2.6% YoY
The stock's P/B is 68% below its 5-year quarterly average of 5.1 and 5% below its last 4 quarters average of 1.7
Intellia Therapeutics's equity has decreased by 25% YoY and by 11% from the previous quarter
The price to sales (P/S) is 72% lower than the 5-year quarterly average of 98.2 and 16% lower than the last 4 quarters average of 32.9
Intellia Therapeutics's revenue has decreased by 21% QoQ and by 13% YoY
Efficiency
How efficient is Intellia Therapeutics business performance
The ROS has contracted by 29% from the previous quarter and by 25% YoY
Intellia Therapeutics's ROE has decreased by 28% YoY and by 9% from the previous quarter
The ROA has contracted by 22% YoY and by 7% from the previous quarter
Intellia Therapeutics's ROIC has decreased by 18% YoY and by 7% from the previous quarter
Dividends
What is NTLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NTLA.
Financial health
How did Intellia Therapeutics financials performed over time
The company's quick ratio fell by 46% YoY and by 17% QoQ
NTLA's current ratio is down by 46% year-on-year and by 15% since the previous quarter
The company's debt is 85% lower than its equity
The company's debt fell by 43% QoQ but it rose by 8% YoY
The debt to equity has contracted by 38% from the previous quarter but it has grown by 36% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.